Little is expected to change at the US FDA in terms of CBD or cannabis policy if president Donald Trump’s nominee Stephen Hahn is approved as commissioner, according to sources contacted by CBD-Intel
Submit your access request to explore how it can streamlines access to critical cannabis insights
"*" indicates required fields